Please use this identifier to cite or link to this item:
|Authors:||Karalapillai, Dharshi;Kaufman, Melissa;Weinberg, Laurence|
|Affiliation:||Austin Health, Melbourne, VIC, Australia. email@example.com|
|Citation:||Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine; 15(1): 57-62|
|Abstract:||Sugammadex is the first selective antagonist to reverse neuromuscular blockade induced by rocuronium and vecuronium. The mechanism by which sugammadex works is superior to current neuromuscular block reversal strategies in terms of speed, efficacy and side effects. There is little contemporary guidance on the use of sugammadex in intensive care medicine. This review covers the key pharmacological features, clinical uses and cost- effectiveness in the context of intensive care practice.|
|Internal ID Number:||23432503|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.